Stock Forecast

  IntegraGen SA ( ALINT.PA) Stock. Should you Buy or Sell?    $ 1.22

0.00 (0.41 %)



IntegraGen SA Analysis

Updated on 10-09-2022
Symbol ALINT.PA
Price $1.22
Beta 0.333
Volume Avg. $4.57 thousand
Market Cap $8.04 M
52 Week Range $0.859 - $2.04


IntegraGen SA opened the day at $1.22 which is +'0.41 % on yesterday's close. IntegraGen SA has a 52 week high of $2.04 and 52 week low of $0.859, which is a difference of $1.181. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $8.04 M and total net profit is $11323959 which means the company is trading at 0.71 times profit to market capitalization. Theoretically, if you were to buy IntegraGen SA for $8.04 M, it would take 15 years to get your money back. IntegraGen SA are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




IntegraGen SA Stock Forecast - Is IntegraGen SA a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreNeutral
DE ScoreStrong Buy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -15.967
Dividend Yiel 0.000
Net Profit Margin -0.063


Valuing IntegraGen SA


Price Book Value Ratio 3.641 Price To Book Ratio 3.641
Price To Sales Ratio 1.003 Price Earnings Ratio -15.967


How liquid is IntegraGen SA


Current Ratio 1.729
Quick Ratio 0.920


Debt


Debt Ratio 0.772 Debt Equity Ratio 3.394
Long Term Debt To Capitalization 0.472 Total Debt To Capitalization 0.000



Latest news about IntegraGen SA






About IntegraGen SA


CEO : Mr. Bernard Courtieu
Sector : Healthcare
Industry : Biotechnology

Website : https://integragen.com

Exchange : Paris

Description :

IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.


My Newsletter

Sign Up For Updates & Newsletters